POPULARITY
3 episodes with evidence based treatment
2 episodes with evidence based treatment
3 episodes with evidence based treatment
3 episodes with evidence based treatment
2 episodes with evidence based treatment
2 episodes with evidence based treatment
2 episodes with evidence based treatment
3 episodes with evidence based treatment
2 episodes with evidence based treatment
Our guest on this episode is Mike Uchrin, Co-founder and CEO of Monogram Health. Founded in 2019, Monogram Health is revolutionizing kidney care through its value based, in-home care model, improving outcomes for patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD) as well as related polychronic conditions. By integrating evidence-based clinical protocols and personalized care delivery, Monogram ensures that CKD patients receive comprehensive support directly in their homes. In the episode, Mike and I discussed: 1) Monogram's value based, in-home care model for CKD and ESKD patients, 2) The importance of multispecialty care and evidence based protocols in improving patient outcomes, 3) Challenges of scaling nationwide while maintaining care quality, and 4) Innovations in kidney care, including genetic and pharmacological breakthroughs.
The Psychology of Self-Injury: Exploring Self-Harm & Mental Health
Emotion Regulation Individual Therapy for Adolescents (ERITA) and its internet-delivered version (IERITA) is just one of a couple of treatments developed specifically to address nonsuicidal self-injury (NSSI) among adolescents. In this episode, Dr. Johan Bjureberg from the Karolinska Institute in Stockholm, Sweden walks us through in detail each of the 11 sessions of IERITA and IERITA's 6 parallel sessions for parents.Learn more about Dr. Bjureberg's work here, and follow the Bjureberg Research Lab and their projects and publications at https://bjureberglab.se/. Below are links to his research on ERITA/IERITA referenced in this episode:Bjureberg, J., Ojala, O., Hesser, H., Häbel, H., Sahlin, H., Gratz, K. L., Tull, M. T., Knutsson, E. C., Hedman-Lagerlöf, E., Ljótsson, B., & Hellner, C. (2023). Effect of internet-delivered Emotion Regulation Individual Therapy for Adolescents with Nonsuicidal Self-Injury Disorder: A randomized clinical trial. JAMA Network Open, 6(7), e2322069.Bjureberg, J., Sahlin, H., Hedman-Lagerlof, E., Gratz, K. L., Tull, M. T., Jokinen, J., Hellner, C., & Ljotsson, B. (2018). Extending research on emotion regulation individual therapy for adolescents (ERITA) with nonsuicidal self-injury disorder: Open pilot trial and mediation analysis of a novel online version. BMC Psychiatry, 18, 326.Bjureberg, J., Sahlin, H., Hellner, C., Hedman-Lagerlof, E., Gratz, K. L., Bjarehed, J., Jokinen, J., Tull, M. T., & Ljotsson, B. (2017). Emotion regulation individual therapy for adolescents with nonsuicidal self-injury disorder: A feasibility study. BMC Psychiatry, 17, 411.Want to have a bigger role on the podcast?:Should you or someone you know be interviewed on the podcast? We want to know! Please fill out this Google doc form, and we will be in touch with more details if it's a good fit.Want to hear your question and have it answered on the podcast? Please send an audio clip of your question (60 seconds or less) to @DocWesters on Instagram or Twitter/X, or email us at thepsychologyofselfinjury@gmail.comWant to be involved in research? Send us a message at thepsychologyofselfinjury@gmail.com and we will see if we can match you to an active study.Want to interact with us through comments and polls? You can on Spotify!Follow Dr. Westers on Instagram and Twitter/X (@DocWesters). To join ISSS, visit itriples.org and follow ISSS on Facebook and Twitter/X (@ITripleS).The Psychology of Self-Injury podcast has been rated as one of the "10 Best Self Harm Podcasts" and "20 Best Clinical Psychology Podcasts" by Feedspot and one of the Top 100 Psychology Podcasts by Goodpods. It has also been featured in Audible's "Best Mental Health Podcasts to Defy Stigma and Begin to Heal." Goodpods Top 100 Parents Podcasts Listen now to The Psychology of Self-Injury: ExploringSelf-Harm & Mental Health podcast Goodpods Top 100 Research Podcasts Listen now to The Psychology of Self-Injury: ExploringSelf-Harm & Mental Health podcast
This is a premium episode with Jamie Reed.This episode is available to paid listeners. To hear the entire conversation, become a paying subscriber here. Jamie will be in The Unspeakeasy as part of our Unspeakers Series on Aug. 7, 2024. Apply to join The Unspeakeasy now if you want the chance to meet her in a private, off-the-record hangout. “What is happening to scores of children . . . is morally and medically appalling.” Those were the words of Jamie Reed, a former case manager at a gender clinic in a major American children's hospital, when she burst on the scene via a Free Press article in February 2023. Since then, she has become known as the most prominent whistleblower in the effort to put the brakes on medicalized gender transition for kids. In this conversation, Jamie talks about what the last year and a half has been like for her, what the public still needs to understand about this issue, and why doctors and other medical providers are continuing to misrepresent their treatment protocols. She discusses how institutions serving the most vulnerable kids, including foster care systems (where large numbers of kids now identify as trans), have adopted affirmative care models and explains what it's like to Testify before state legislatures about restricting access to non-evidence-based gender-affirming care. As a self-described “queer woman who's married to a transgender person and is politically to the left of Bernie Sanders,” it's the last thing she ever thought she'd be doing. Now it's her life's work. GUEST BIO Jamie Reed is one of the first public whistleblowers from a pediatric gender clinic in the United States and is now the Executive Director and Co-Founder of the LGBT Courage Coalition, an American-based non-profit of LGBT adults seeking to reform youth gender medicine. She has spoken at numerous conferences including Genspect: The Bigger Picture in Colorado, at the International Perspectives on Evidence- Based Treatment for Gender-Dysphoric Youth in New York, and Psychotherapeutic Process with Young People Experiencing Gender Dysphoria in Tampere, Finland. Jamie is a gay woman and foster and adoptive parent of five boys. She holds a Master of Science in Clinical Research from Washington University in St. Louis and a bachelor's degree in Cultural Anthropology. Read the original story in The Free Press here. Want to hear the whole conversation? Upgrade your subscription here. HOUSEKEEPING ✈️ 2024 Unspeakeasy Retreats — See where we'll be in 2024! https://bit.ly/3Qnk92n
Featuring perspectives from Dr Nikhil I Khushalani and Dr Jason J Luke, including the following topics: Introduction (0:00) Evidence-Based Treatment of Nonmetastatic and Metastatic Melanoma — Dr Luke (2:49) Optimizing the Management of Nonmelanoma Skin Cancers — Dr Khushalani (36:54) CME information and select publications
We'll be joined from right here in Austin by Marcela Cabay, of Ria Health, which uses an evidence-based approach to addiction that is vastly different from the 12-step programs. And Dr. Mara with more on living a passionate life through the obstacles of life.
We'll be joined from right here in Austin by Marcela Cabay, of Ria Health, which uses an evidence-based approach to addiction that is vastly different from the 12-step programs. And Dr. Mara with more on living a passionate life through the obstacles of life.
With support from our colleagues at Penumbra, learn more about the speed, safety, and simplicity of CAVT for clot detection and removal.
On episode 26 of A Chat with Uma, I dedicate a full episode to OCD awareness, in honor of OCD Awareness Week 2023. I provide a full primer on OCD 101 - all about what OCD is NOT, and what it IS. I share my full OCD story of onset, symptoms, misdiagnosis, delayed treatment, incorrect treatment, and what evidence-based treatment has looked like. I speak at length about my non-linear path within treatment, normalizing the coexistence of both suffering and recovery at once. I dismantle misconceptions and bust pervasive myths about what OCD is considered to be by popular culture, and discuss the repercussions of misinformation around OCD. Above all, I provide empowerment, validation, and hope around the OCD experience through speaking openly and honestly about all facets of living with obsessive-compulsive disorder. Topics Discussed (+ timestamps): (00:00:00) Intro, overview, why I am recording this episode today (00:13:04) UPCOMING EVENT: Made of Millions OCD Socratic Seminar: BIPOC Representation in the OCD Space Mon. 10/9, 8 ET Livestream on @MadeOfMillions TikTok + replay on IG (00:14:21) UPCOMING EVENT: IOCDF Live Stream Panel - Diversity Starts With UsTues. 9/26, 7 ET Thurs. 10/12, 7pm ET Link to attend (00:15:13) UPCOMING EVENT: IOCDF Advocate Instagram Live Sat. 10/14, 12pm ET Attend: @IOCDF Instagram Live (00:15:55) UPCOMING EVENT: OCD Gamechangers: Live Advocate Virtual Event Sat. 10/14, 7:30pm ET Attend: OCD Gamechangers YouTube or Facebook Live (00:17:04) UPCOMING EVENT + ANNOUNCEMENT: Online OCD Conference - KEYNOTE ADDRESS! Sat. 10/21, 6pm ET Register here (00:18:16) ANNOUNCEMENT: Joining OCD Wisconsin's Board of Directors (00:20:25) What OCD is NOT: A choice An adjective A quirk Ego-syntonic (it's ego-DYStonic) Nobody "is a little OCD" or "has a little OCD" Why misrepresentation of OCD leads to misdiagnosis & mistreatment (00:38:18) What OCD actually IS: DSM-5 definition of "obsessions" DSM-5 definition of "compulsions" OCD themes & subtypes Taboo obsessional themes within OCD Mental compulsions & rituals The shame of OCD Why rationality, logic, & reason do not permeate the "OCD brain" How OCD is fully ego-DYStonic The doubting disease Anxiety vs. OCD (00:54:22) My FULL OCD story What OCD looked like for me in childhood How it fully took over by adolescence How I hit rock bottom in early adulthood and lost all functionality How I finally received a diagnosis at 22 13 years of no diagnosis or treatment 22 years of misdiagnosis 12 years of incorrect treatment 25 years without proper intervention Finding evidence-based treatment at 25 Contextual episodes: 01. My Full Story: 0 to 26 02-04. My Mental Health Journey: Part 1, Part 2, Part 3 (01:33:24) What evidence-based treatment & recovery has looked like for me My experience of comorbid OCD & PTSD (01:45:02) Reconciling the time lost to misdiagnosis & lack of treatment How OCD led me to join a religious cult at 14 Grief and loss (01:55:04) Rapid-fire final OCD myth busting: OCD is NOT an anxiety disorder (& is not treated as such) OCD is NOT "just" a form of anxiety (disgust, guilt, shame, just-rightness, etc.) OCD is NOT a form of trauma OCD is NOT a form of PTSD (& is not treated as such) OCD is also a neurodevelopment disorder Connect with me! My website: umarchatterjee.com Video + event recording repository Instagram: @UmaRChatterjee Twitter: @UmaRChatterjee TikTok: @UmaRChatterjee Email: hello@umarchatterjee.com Support my work: https://ko-fi.com/umarchatterjee Have a guest you want on the show? Fill out the Guest Suggestion Form! --- Send in a voice message: https://podcasters.spotify.com/pod/show/umarchatterjee/message
Mouth Taping: Viral Fad or Evidence-Based Treatment for Mouth Breathing? By Tanya L. Smith, RDH, BS Original article published on Today's RDH: https://www.todaysrdh.com/mouth-taping-viral-fad-or-evidence-based-treatment-for-mouth-breathing/ This audio article is sponsored by LISTERINE®. Although LISTERINE® Antiseptic is the most extensively tested over-the-counter mouthrinse in the world, with over 30 long-term clinical trials examining its safety and efficacy, there is still some misinformation out there over the uses of mouthrinses containing alcohol. To help understand the safety of alcohol-containing mouthrinses, in case any patients ask you about it, head on over to https://rdh.tv/ListerineSafety Need CE? Start earning CE credits today at https://rdh.tv/ce Get daily dental hygiene articles at https://www.todaysrdh.com Follow Today's RDH on Facebook: https://www.facebook.com/TodaysRDH/ Follow Kara RDH on Facebook: https://www.facebook.com/DentalHygieneKaraRDH/ Follow Kara RDH on Instagram: https://www.instagram.com/kara_rdh/ *Although a sponsor of this audio article, LISTERINE® and Johnson & Johnson Consumer Inc. had no input into or control over the content being presented in this podcast.
This episode focuses on the appropriate and inappropriate treatment when caring for a patient who has been bitten by a venomous snake.---This is episode 1 of the series: Envenomations: Snakes, Lizards, Marine Life, and ArthropodsEnvenomations, particularly snakebites, are common in Southern states, yet most healthcare professionals have little formal training on this subject. Frequently, the medical care provided is inconsistent with established guidelines. There are a variety of common mistakes of both omission and commission. Antivenom is not administered when it is indicated, and antibiotics and surgical interventions are ordered despite the evidence indicating these are unnecessary. Many soft tissue infections are mis-diagnosed as spider bites and hymenoptera stings often receive unnecessary and potentially dangerous treatments.This podcast reviews the pathophysiology, clinical features, and management of various envenomations, including snakebites, scorpion stings, spider bites, hymenoptera stings, bites from venomous lizards and a variety of marine envenomations, including jellyfish stings. Common myths will be dispelled, and learners will be provided with evidence-based treatment guidelines.Nurses may be able to complete an accredited CE activity featuring content from this podcast and earn CE hours provided from Elite Learning by Colibri Healthcare. For more information, click hereView Episode Show NotesView Episode TranscriptAlready an Elite Member? Login hereLearn more about CE Podcasts from Elite Learning by Colibri HealthcareView this podcast course on Elite LearningSeries: Envenomations: Snakes, Lizards, Marine Life, and Arthropods
The Pharm So Hard Podcast: An Emergency Medicine and Hospital Pharmacy Podcast
The post Episode 101. Aspiration Pneumonia: Antibiotic Stewardship and Evidence-Based Treatment Strategies appeared first on The Pharm So Hard Podcast.
Hour 3 of The Autism Network Podcastathon Dr. Doreen Granpeesheh shares essential information about anxiety, particularly as it relates to autism. Viewer questions are encouraged. Autism expert Dr. Doreen Granpeesheh gives the definitive talk about anxiety as it relates to autism. Anxiety has a great deal to do with a person's ability to cope, learn, and grow. Masking the anxiety is not always the answer. Listen as Dr. Doreen talks about successful ways to treat, and overcome the debilitating side of anxiety, so we can productively get back to learning and living. Dr. Doreen Granpeesheh Dr. Doreen Granpeesheh has dedicated over forty years to helping individuals with autism lead healthy, productive lives. She is licensed as a psychologist in California, Texas, Virginia, Oregon, Colorado, Michigan and Arizona and holds a Certificate of Professional Qualification in Psychology from the Association of State and Provincial Psychology Boards. She is a doctoral level Board Certified Behavior Analyst and is licensed as a behavior analyst in Arizona, New York, Nevada, Louisiana and Virginia. Dr. Granpeesheh began her studies in autism as an undergraduate at UCLA earning a bachelor's degree in 1984, and a Master's degree in psychology in 1987, followed by a Ph.D. in psychology from UCLA in 1990. While completing her degrees, Dr. Granpeesheh worked with Dr. Ivar Lovaas on the groundbreaking outcome study published in 1987 which showed a recovery rate of close to 50% among the study's research participants. Dr. Granpeesheh built on Dr. Lovaas's work, developing the CARD Model, which is a comprehensive, evidence-based approach to treating autism. In 1990, Dr. Granpeesheh founded the Center for Autism and Related Disorders, also known as CARD. Under Dr. Granpeesheh's 30 years of leadership, CARD became one of the world's largest providers of ABA-based treatment for individuals diagnosed with autism spectrum disorder. With over 260 locations throughout the United States and internationally, CARD employed over 6,000 highly skilled professionals, and was a leading employer of Board Certified Behavior Analysts (BCBAs) providing behavioral treatment to thousands of families worldwide. CARD's highly regarded behavior management and skill acquisition programs were the culmination of decades of research in the field of autism treatment. As part of the nation's third largest non-governmental organization contributing to autism research, CARD researchers published groundbreaking studies that contributed significantly to the field of autism treatment research. In 2011, Dr. Granpeesheh founded Autism Research Group, a nonprofit organization whose mission was to identify and conduct treatment research that improves the quality of life for individuals with autism spectrum disorder. To increase access to evidence-based treatment, Dr. Granpeesheh founded Skills™, an innovative web-based platform that optimizes treatment programs for individuals with autism spectrum disorder. Skills™ provides comprehensive assessment and curriculum, positive support planning for challenging behavior, progress tracking, and treatment evaluation. and enables healthcare professionals, teachers, parents, and/or caregivers to design and manage comprehensive, individualized treatment programs for children and adolescents with autism spectrum disorder as well as tracking progress in real time by collecting and uploading data electronically. From 1990 to 2019, as CARD's CEO and chief clinician, Dr. Granpeesheh developed extensive state-of-the-art training programs for CARD's clinical employees, parents and caregivers, and school personnel. As demand for CARD training programs increased, Dr. Granpeesheh established the Institute for Behavioral Training which provides web-based and in-person training programs targeting the specific training needs of school districts, parents and caregivers, physicians, and autism treatment providers. Dr. Granpeesheh has been a member of numerous scientific and advisory boards including the US Autism and Asperger's Association, The Autism File Journal, Autism 360-Medigenesis, the 4-A Healing Foundation and the Defeat Autism Now coalition. In addition, Dr. Granpeesheh has served on the National Board of Directors of the Autism Society of America (ASA), the practice board of The Association for Behavior Analysis International (ABAI) as well as the Autism Human Rights and Discrimination Initiative Steering Committee, the Early Intervention Taskforce of the Senate Select Committee on Autism and Related Disorders and the Oversight Committee of the Department of Developmental Disabilities. In 2008, Dr. Granpeesheh produced and co-directed the documentary “Recovered: Journeys through the Autism Spectrum and Back”, a film about 4 children diagnosed with Autism who, after three years of intensive intervention, recovered and now lead productive and healthy lives. This documentary received significant recognition including “Best Documentary” in the Director's Chair Film Festival, official selection in the Victoria Independent Film Festival and special recognition in the ReelHeART International Film Festival of Toronto. As one of the foremost experts in autism diagnosis and treatment, Dr. Granpeesheh has appeared on numerous TV shows including Dr. Phil, the Doctors, Fox and Friends and other notable news segments to shed light on and answer questions regarding autism. In August 2009, her research entitled “Retrospective Analysis of Clinical Records in 38 Cases of Recovery from Autism” was published in the Annals of Clinical Psychiatry, showing that recovery from autism is possible with early, intensive intervention using ABA. This study echoed the results of Dr. Lovaas's earlier study and garnered Dr. Granpeesheh the prestigious George Winokur Clinical Research Award. In 2014, Dr. Granpeesheh co-authored the book Evidence-Based Treatment for Children with Autism, a comprehensive description of the model of treatment she developed over her 30 years of leadership at CARD. She has also authored over 50 peer reviewed publications on subjects concerning the diagnosis and treatment of Autism. In 2015, Dr. Granpeesheh co-authored a series of 4 articles that were published in the prestigious journal Pediatrics. These articles were the culmination of work from several think tanks concerning the early diagnosis and treatment of autism and continue to define the guiding principles of therapeutic process for medical and psychological professionals today. Dr. Granpeesheh is co-founder of The Autism Media Network which hosts “Autism Live”, the number one video podcast in the field of autism education. Since 2012, Dr. Granpeesheh has broadcast the “Dr. Doreen Show” on Autism Live, a weekly interactive web show providing support, resources, information, facts, entertainment, and inspiration to parents, teachers, and practitioners who work with individuals on the autism spectrum. Through the Ask Dr. Doreen Show, hundreds of families have been able to call in or write in and gain immediate guidance on various issues pertaining to their children. In 2022, Autism Media Network launched “Stories from the Spectrum” the first show to be entirely produced, directed by and featuring individuals on the spectrum of autism. In 2020, Dr. Granpeesheh retired as CEO of CARD and continues to contribute to the autism community as founding member and president of Autism Care Today (ACT), a nonprofit organization that she co-founded in 2005. ACT builds awareness and provides grant funding to families struggling with autism. In addition, Dr. Granpeesheh remains a member of the Finance Committee of The Association for Behavior Analysis International, sits on the board of advisors of the Board of Psychology of UCLA, and is a member of the Board of Directors of the Behavioral Health Center of Excellence. In 2020, the Society for the Advancement of Behavior Analysis honored her by establishing the “Doreen Granpeesheh Fund for the Interdisciplinary Approach to the Treatment of Autism”, whose objective is to support educational pursuits that complement the behavioral treatment of autism with knowledge and expertise from related fields and with consideration of the individual as a whole. Dr. Granpeesheh remains committed to improving treatment efficacy by expanding the knowledge of behavior analysts to include a broad understanding of the diagnostic criteria, dietary protocols, and biomedical interventions currently in use for the treatment of autism. Awards and Accolades: 2007: The Autism Society of America's Wendy F. Miller Professional of the Year Award 2009: American Academy of Clinical Psychiatrists: George Winokur Clinical Research Award 2009: Autism Around the World: Appreciation Award 2010: Recognition by Mayor of Los Angeles, Antonio Villaraigosa for 20 years of commitment and dedication to the treatment of autism. 2010: Recognition and gratitude by Governor of California, Arnold Schwarzenegger for provision of support and treatment for those affected by autism in California. 2010: Autism Around the World: Appreciation Award 2011: Universal Love Foundation's Parent of Distinction Award 2012: Recognition from The Senate of the State of California Taskforce on Equity and Diversity, for exemplary leadership and inspiring contributions in promoting equality for all individuals who are overcoming the challenges of autism spectrum disorders. 2013: National Association of Professional Women for Outstanding Excellence and Dedication to Her Profession and the Achievement of Women 2014: Parenting Arizona: Raising the Bar Award 2015: The San Fernando Valley Business Journal's Women in Business Lifetime Achievement Award 2015: The NW Autism Foundation Champion of Autism Award 2015: Innovations in Healthcare Abby Award Finalist 2017: CODiE Best Solutions for Special Needs Students Award 2019: Autism Care Today's Denim Diamond and Stars Visionary Award 2021: Society for the Advancement of Behavior Analysis: Award for Enduring Programmatic Contributions to the Field. Resources: https://www.autismnetwork.com/category/ask-dr-doreen/ https://www.tiktok.com/@askdrdoreen https://www.instagram.com/askdrdoreen/
Go online to PeerView.com/NNK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of patients with hepatocellular carcinoma (HCC) have been nothing short of revolutionary. But what does this revolution in care mean for your patients? In this activity, based on a recent live symposium, a multidisciplinary panel of experts shares best practices for providing personalized medicine that incorporates newer therapy options, including immunotherapy-based combinations in the first-line setting. With discussion of cases drawn from clinical practice, the panel will link the latest data and research to real-world patient care and provide guidance on selecting and sequencing treatments as patients continue to the second line and beyond, and which emerging strategies are set to bring further changes to HCC outcomes. Our panel will also focus on treatment of patients in the early and intermediate stages, including innovative multimodal strategies and the importance of integrating systemic therapy into earlier stages of disease. Upon completion of this activity, participants should be better able to: Summarize clinical evidence on approved and emerging immunotherapy, targeted, antiangiogenic, and combination-based platforms across HCC settings and patient populations; Recommend individualized, evidence-based approaches to treatment selection and sequencing for patients with advanced HCC over multiple lines of therapy; and Develop strategies to improve treatment delivery, tolerability, and safety management for patients with HCC receiving modern therapies
Go online to PeerView.com/NNK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of patients with hepatocellular carcinoma (HCC) have been nothing short of revolutionary. But what does this revolution in care mean for your patients? In this activity, based on a recent live symposium, a multidisciplinary panel of experts shares best practices for providing personalized medicine that incorporates newer therapy options, including immunotherapy-based combinations in the first-line setting. With discussion of cases drawn from clinical practice, the panel will link the latest data and research to real-world patient care and provide guidance on selecting and sequencing treatments as patients continue to the second line and beyond, and which emerging strategies are set to bring further changes to HCC outcomes. Our panel will also focus on treatment of patients in the early and intermediate stages, including innovative multimodal strategies and the importance of integrating systemic therapy into earlier stages of disease. Upon completion of this activity, participants should be better able to: Summarize clinical evidence on approved and emerging immunotherapy, targeted, antiangiogenic, and combination-based platforms across HCC settings and patient populations; Recommend individualized, evidence-based approaches to treatment selection and sequencing for patients with advanced HCC over multiple lines of therapy; and Develop strategies to improve treatment delivery, tolerability, and safety management for patients with HCC receiving modern therapies
Go online to PeerView.com/NNK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of patients with hepatocellular carcinoma (HCC) have been nothing short of revolutionary. But what does this revolution in care mean for your patients? In this activity, based on a recent live symposium, a multidisciplinary panel of experts shares best practices for providing personalized medicine that incorporates newer therapy options, including immunotherapy-based combinations in the first-line setting. With discussion of cases drawn from clinical practice, the panel will link the latest data and research to real-world patient care and provide guidance on selecting and sequencing treatments as patients continue to the second line and beyond, and which emerging strategies are set to bring further changes to HCC outcomes. Our panel will also focus on treatment of patients in the early and intermediate stages, including innovative multimodal strategies and the importance of integrating systemic therapy into earlier stages of disease. Upon completion of this activity, participants should be better able to: Summarize clinical evidence on approved and emerging immunotherapy, targeted, antiangiogenic, and combination-based platforms across HCC settings and patient populations; Recommend individualized, evidence-based approaches to treatment selection and sequencing for patients with advanced HCC over multiple lines of therapy; and Develop strategies to improve treatment delivery, tolerability, and safety management for patients with HCC receiving modern therapies
Go online to PeerView.com/NNK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of patients with hepatocellular carcinoma (HCC) have been nothing short of revolutionary. But what does this revolution in care mean for your patients? In this activity, based on a recent live symposium, a multidisciplinary panel of experts shares best practices for providing personalized medicine that incorporates newer therapy options, including immunotherapy-based combinations in the first-line setting. With discussion of cases drawn from clinical practice, the panel will link the latest data and research to real-world patient care and provide guidance on selecting and sequencing treatments as patients continue to the second line and beyond, and which emerging strategies are set to bring further changes to HCC outcomes. Our panel will also focus on treatment of patients in the early and intermediate stages, including innovative multimodal strategies and the importance of integrating systemic therapy into earlier stages of disease. Upon completion of this activity, participants should be better able to: Summarize clinical evidence on approved and emerging immunotherapy, targeted, antiangiogenic, and combination-based platforms across HCC settings and patient populations; Recommend individualized, evidence-based approaches to treatment selection and sequencing for patients with advanced HCC over multiple lines of therapy; and Develop strategies to improve treatment delivery, tolerability, and safety management for patients with HCC receiving modern therapies
Go online to PeerView.com/NNK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of patients with hepatocellular carcinoma (HCC) have been nothing short of revolutionary. But what does this revolution in care mean for your patients? In this activity, based on a recent live symposium, a multidisciplinary panel of experts shares best practices for providing personalized medicine that incorporates newer therapy options, including immunotherapy-based combinations in the first-line setting. With discussion of cases drawn from clinical practice, the panel will link the latest data and research to real-world patient care and provide guidance on selecting and sequencing treatments as patients continue to the second line and beyond, and which emerging strategies are set to bring further changes to HCC outcomes. Our panel will also focus on treatment of patients in the early and intermediate stages, including innovative multimodal strategies and the importance of integrating systemic therapy into earlier stages of disease. Upon completion of this activity, participants should be better able to: Summarize clinical evidence on approved and emerging immunotherapy, targeted, antiangiogenic, and combination-based platforms across HCC settings and patient populations; Recommend individualized, evidence-based approaches to treatment selection and sequencing for patients with advanced HCC over multiple lines of therapy; and Develop strategies to improve treatment delivery, tolerability, and safety management for patients with HCC receiving modern therapies
Go online to PeerView.com/NNK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of patients with hepatocellular carcinoma (HCC) have been nothing short of revolutionary. But what does this revolution in care mean for your patients? In this activity, based on a recent live symposium, a multidisciplinary panel of experts shares best practices for providing personalized medicine that incorporates newer therapy options, including immunotherapy-based combinations in the first-line setting. With discussion of cases drawn from clinical practice, the panel will link the latest data and research to real-world patient care and provide guidance on selecting and sequencing treatments as patients continue to the second line and beyond, and which emerging strategies are set to bring further changes to HCC outcomes. Our panel will also focus on treatment of patients in the early and intermediate stages, including innovative multimodal strategies and the importance of integrating systemic therapy into earlier stages of disease. Upon completion of this activity, participants should be better able to: Summarize clinical evidence on approved and emerging immunotherapy, targeted, antiangiogenic, and combination-based platforms across HCC settings and patient populations; Recommend individualized, evidence-based approaches to treatment selection and sequencing for patients with advanced HCC over multiple lines of therapy; and Develop strategies to improve treatment delivery, tolerability, and safety management for patients with HCC receiving modern therapies
The Psychology of Self-Injury: Exploring Self-Harm & Mental Health
A lot of therapies address the context in which nonsuicidal self-injury (NSSI) and self-harm may occur, but only a few treatments have been designed to address NSSI specifically. In this episode, we dive into one of these treatments: Emotion Regulation Group Therapy (ERGT). Drs. Kim Gratz and Matthew Tull from the University of Toledo in Ohio walk us through in significant detail each of the 90-minute 14 sessions of ERGT.Learn more about Dr. Gratz here and reach her at klgratz28@gmail.com. Learn more about Dr. Tull here and follow him on Twitter @MTTull. Learn more about the Personality and Emotion Research and Treatment (PERT) Laboratory within the Department of Psychology at the University of Toledo here, and follow the PERT Lab on Twitter @LabPert. Below are links to their research on ERGT referenced in this episode:Gratz, K. L., & Gunderson, J. G. (2006). Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with Borderline Personality Disorder. Behavior Therapy, 37(1), 25-35.Gratz, K. L., & Tull, M. T. (2011). Extending research on the utility of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality pathology. Personality Disorders: Theory, Research, and Treatment, 2(4), 316–326.Gratz, K. L., Tull, M. T., & Levy, R. (2014). Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychological Medicine, 44, 2099–2112.Gratz, K. L., Bardeen, J. R., Levy, R., Dixon-Gordon, K., L., & Tull, M. T. (2015). Mechanisms of change in an emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Behaviour Research and Therapy, 65, 29-35.Sahlin, H., Bjureberg, J., Gratz, K. L., Tull, M. T., Hedman, E., Bjarehed, J., Jokinen, J., Lundh, L., Ljotsson, B., & Hellner, C. (2017). Emotion regulation group therapy for deliberate self-harm: A multi-site evaluation in routine care using an uncontrolled open trial design. BMJ Open, 7(10), e016220.Follow Dr. Westers on Instagram and Twitter (@DocWesters). To join ISSS, visit itriples.org and follow ISSS on Facebook and Twitter (@ITripleS).The Psychology of Self-Injury podcast has been rated #5 by Feedspot in their "Best 20 Clinical Psychology Podcasts" and by Welp Magazine in their "20 Best Injury Podcasts."
I had a great sit down with Dr. Kimberly Applewhite right before the Holidays where we talked about the importance of connection in a world that too often values individualism. Most of us know by this point that relationships matter to our quality of lives. At the same time navigating interpersonal situations is challenging. So whether you are facing holiday seasons, family get-togethers, or just run-of-the-mill daily living… this is a great episode to help foster emotional and community intelligence. Kimberly Applewhite, PsyD. Is a licensed psychologist at the Utah Center for Evidence Based Treatment. She specializes in dialectical behavior therapy (DBT), cognitive behavioral therapy (CBT) and motivational interviewing (MI) for health related stressors. She received a Bachelor of Arts in Psychology from New York University; and a Masters of Science in School Psychology and Doctorate of Psychology in School-Clinical Child Psychology from the Ferkauf Graduate School of Psychology at Yeshiva University (APA Accredited). Her graduate school focus was on assessment and treatment of children and families in bio-psycho social-spiritual contexts, as well as treatment of ethnic minorities and LGBTQ+ populations. Please consider donating to keep this podcast going at natashahelfer.com. Intro ("Fisher's Hornpipe") and outro by Otter Creek Podcast edited by: Ashley Pacini
We are both proponents of seeking safety as a therapy for people with trauma and substance use. This is a very low barrier treatment for both the therapist or peer support worker to learn AND for the patient to get access to. For myself, when I'm working with people who use drugs, it's a great standalone treatment AND a great gateway therapy to more intensive work. Here are some resources: Seeking Safety https://www.treatment-innovations.org/seeking-safety.html Basic handouts for seeking safety https://www.treatment-innovations.org/uploads/2/5/5/5/25555853/1-4-2022-basic-handouts-for-ppl-without-books.pdf Here is a video where Dr. Lisa covers the basics https://youtu.be/3yaDgYEZB3I Here is a video where an educator covers the basics https://youtu.be/Zdb3D4MyCoY A very well done talk on seeking safety Implementation https://youtu.be/qNNvDl3XTII Featuring addiction psychiatrist Dr. Wiplove (Wip) Lamba, addictions case manager and former addict Jean-Paul (JP) Michael, along with their guests discuss all things related to substance use, addiction, addiction medicine, psychotherapy, harm reduction, treatment and recovery. Wip and JP share their motivation, curiosity, and passion for their craft. JP works on a daily basis in a renown inner city hospital in Canada's largest city. This work is separate from Wiplove's clinical and academic work. The content should not be taken as direct medical advice or clinical instruction. #Addiction #Psychotherapy #Caseworker #Healthcare provider #Healthcare provider education #captainhooked #Psychiatry #addiction medicine #Seeking safety #Dr. Najavits
Cognitive Behavioral Therapy for Insomnia (CBT-I) is an evidence-based approach to insomnia. Here is Doctor Nissen's description of the CBT-I methodology. Brain Health with Dr. Nissen brings you advancements in medicine, #neuroscience, psychiatry, and #nutrition to help you live a better life. Dr. Nissen's expert interviews reveal new, evidence-based approaches to enhancing mental health, sharpening cognition, and optimizing performance. With topics such as #Alzheimer's disease, #neuromodulation, #depression, the Mediterranean #Diet, and #psychedelics, this show is sure to expose listeners to new topics on the frontiers of medicine and neuroscience. Join our community at DrNissen.com Support us on Patreon: https://www.patreon.com/drnissen Subscribe to the podcast at https://podcasts.apple.com/us/podcast/brain-health-with-dr-nissen/id1510757864 Dr. Nissen is a medical doctor (M.D.) and therapist. This show is intended for entertainment and educational purposes only and does not substitute personalized medical advice. Please speak with your doctor before attempting any medical or major diet and lifestyle changes. Check out Dr. Nissen's children's book on empathy and emotional intelligence, Emily Empathy! http://bit.ly/emilyempathy #depression #mentalhealth #wellness #health #healthylifestyle #medicine #treatment #medical #healthcare #psychotherapy #psychedelics #psychedelictherapy
Go online to PeerView.com/DPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence and validation of the Bruton tyrosine kinase (BTK) inhibitor agent class in chronic lymphocytic leukemia (CLL) has informed the modern, more personalized approach to patient management—are you prepared to challenge your skills and see how the experts navigate this changed clinical landscape? Find out by viewing this Clinical Consults educational activity recorded at the annual European hematology meeting in Vienna; throughout experts will explore the evidence-based use of BTK inhibitors in these different CLL settings. Tune in to see case-based guidance on modern, customized therapy selection based on prognostic factors, safety and selectivity differences between available agents, and treatment settings in the context of EU and US practice. Upon completion of this activity, participants should be better able to: Describe current evidence from pivotal clinical trials, head-to-head comparisons, and practice guidelines on BTK inhibitor efficacy, safety, and mechanistic/selectivity differences, including as single-agent approaches or as part of novel combinations; Select personalized BTK inhibitor therapy for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Recommend sequential BTK inhibitor options for the management of patients with relapsed/refractory CLL or for individuals who develop therapeutic intolerance; and Develop a management plan for adverse events associated with first- and second-generation BTK inhibitors used to treat CLL.
Go online to PeerView.com/DPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence and validation of the Bruton tyrosine kinase (BTK) inhibitor agent class in chronic lymphocytic leukemia (CLL) has informed the modern, more personalized approach to patient management—are you prepared to challenge your skills and see how the experts navigate this changed clinical landscape? Find out by viewing this Clinical Consults educational activity recorded at the annual European hematology meeting in Vienna; throughout experts will explore the evidence-based use of BTK inhibitors in these different CLL settings. Tune in to see case-based guidance on modern, customized therapy selection based on prognostic factors, safety and selectivity differences between available agents, and treatment settings in the context of EU and US practice. Upon completion of this activity, participants should be better able to: Describe current evidence from pivotal clinical trials, head-to-head comparisons, and practice guidelines on BTK inhibitor efficacy, safety, and mechanistic/selectivity differences, including as single-agent approaches or as part of novel combinations; Select personalized BTK inhibitor therapy for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Recommend sequential BTK inhibitor options for the management of patients with relapsed/refractory CLL or for individuals who develop therapeutic intolerance; and Develop a management plan for adverse events associated with first- and second-generation BTK inhibitors used to treat CLL.
Go online to PeerView.com/DPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence and validation of the Bruton tyrosine kinase (BTK) inhibitor agent class in chronic lymphocytic leukemia (CLL) has informed the modern, more personalized approach to patient management—are you prepared to challenge your skills and see how the experts navigate this changed clinical landscape? Find out by viewing this Clinical Consults educational activity recorded at the annual European hematology meeting in Vienna; throughout experts will explore the evidence-based use of BTK inhibitors in these different CLL settings. Tune in to see case-based guidance on modern, customized therapy selection based on prognostic factors, safety and selectivity differences between available agents, and treatment settings in the context of EU and US practice. Upon completion of this activity, participants should be better able to: Describe current evidence from pivotal clinical trials, head-to-head comparisons, and practice guidelines on BTK inhibitor efficacy, safety, and mechanistic/selectivity differences, including as single-agent approaches or as part of novel combinations; Select personalized BTK inhibitor therapy for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Recommend sequential BTK inhibitor options for the management of patients with relapsed/refractory CLL or for individuals who develop therapeutic intolerance; and Develop a management plan for adverse events associated with first- and second-generation BTK inhibitors used to treat CLL.
Go online to PeerView.com/DPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence and validation of the Bruton tyrosine kinase (BTK) inhibitor agent class in chronic lymphocytic leukemia (CLL) has informed the modern, more personalized approach to patient management—are you prepared to challenge your skills and see how the experts navigate this changed clinical landscape? Find out by viewing this Clinical Consults educational activity recorded at the annual European hematology meeting in Vienna; throughout experts will explore the evidence-based use of BTK inhibitors in these different CLL settings. Tune in to see case-based guidance on modern, customized therapy selection based on prognostic factors, safety and selectivity differences between available agents, and treatment settings in the context of EU and US practice. Upon completion of this activity, participants should be better able to: Describe current evidence from pivotal clinical trials, head-to-head comparisons, and practice guidelines on BTK inhibitor efficacy, safety, and mechanistic/selectivity differences, including as single-agent approaches or as part of novel combinations; Select personalized BTK inhibitor therapy for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Recommend sequential BTK inhibitor options for the management of patients with relapsed/refractory CLL or for individuals who develop therapeutic intolerance; and Develop a management plan for adverse events associated with first- and second-generation BTK inhibitors used to treat CLL.
Go online to PeerView.com/DPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence and validation of the Bruton tyrosine kinase (BTK) inhibitor agent class in chronic lymphocytic leukemia (CLL) has informed the modern, more personalized approach to patient management—are you prepared to challenge your skills and see how the experts navigate this changed clinical landscape? Find out by viewing this Clinical Consults educational activity recorded at the annual European hematology meeting in Vienna; throughout experts will explore the evidence-based use of BTK inhibitors in these different CLL settings. Tune in to see case-based guidance on modern, customized therapy selection based on prognostic factors, safety and selectivity differences between available agents, and treatment settings in the context of EU and US practice. Upon completion of this activity, participants should be better able to: Describe current evidence from pivotal clinical trials, head-to-head comparisons, and practice guidelines on BTK inhibitor efficacy, safety, and mechanistic/selectivity differences, including as single-agent approaches or as part of novel combinations; Select personalized BTK inhibitor therapy for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Recommend sequential BTK inhibitor options for the management of patients with relapsed/refractory CLL or for individuals who develop therapeutic intolerance; and Develop a management plan for adverse events associated with first- and second-generation BTK inhibitors used to treat CLL.
Go online to PeerView.com/DPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence and validation of the Bruton tyrosine kinase (BTK) inhibitor agent class in chronic lymphocytic leukemia (CLL) has informed the modern, more personalized approach to patient management—are you prepared to challenge your skills and see how the experts navigate this changed clinical landscape? Find out by viewing this Clinical Consults educational activity recorded at the annual European hematology meeting in Vienna; throughout experts will explore the evidence-based use of BTK inhibitors in these different CLL settings. Tune in to see case-based guidance on modern, customized therapy selection based on prognostic factors, safety and selectivity differences between available agents, and treatment settings in the context of EU and US practice. Upon completion of this activity, participants should be better able to: Describe current evidence from pivotal clinical trials, head-to-head comparisons, and practice guidelines on BTK inhibitor efficacy, safety, and mechanistic/selectivity differences, including as single-agent approaches or as part of novel combinations; Select personalized BTK inhibitor therapy for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Recommend sequential BTK inhibitor options for the management of patients with relapsed/refractory CLL or for individuals who develop therapeutic intolerance; and Develop a management plan for adverse events associated with first- and second-generation BTK inhibitors used to treat CLL.
Go online to PeerView.com/DPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence and validation of the Bruton tyrosine kinase (BTK) inhibitor agent class in chronic lymphocytic leukemia (CLL) has informed the modern, more personalized approach to patient management—are you prepared to challenge your skills and see how the experts navigate this changed clinical landscape? Find out by viewing this Clinical Consults educational activity recorded at the annual European hematology meeting in Vienna; throughout experts will explore the evidence-based use of BTK inhibitors in these different CLL settings. Tune in to see case-based guidance on modern, customized therapy selection based on prognostic factors, safety and selectivity differences between available agents, and treatment settings in the context of EU and US practice. Upon completion of this activity, participants should be better able to: Describe current evidence from pivotal clinical trials, head-to-head comparisons, and practice guidelines on BTK inhibitor efficacy, safety, and mechanistic/selectivity differences, including as single-agent approaches or as part of novel combinations; Select personalized BTK inhibitor therapy for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Recommend sequential BTK inhibitor options for the management of patients with relapsed/refractory CLL or for individuals who develop therapeutic intolerance; and Develop a management plan for adverse events associated with first- and second-generation BTK inhibitors used to treat CLL.
Go online to PeerView.com/DPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence and validation of the Bruton tyrosine kinase (BTK) inhibitor agent class in chronic lymphocytic leukemia (CLL) has informed the modern, more personalized approach to patient management—are you prepared to challenge your skills and see how the experts navigate this changed clinical landscape? Find out by viewing this Clinical Consults educational activity recorded at the annual European hematology meeting in Vienna; throughout experts will explore the evidence-based use of BTK inhibitors in these different CLL settings. Tune in to see case-based guidance on modern, customized therapy selection based on prognostic factors, safety and selectivity differences between available agents, and treatment settings in the context of EU and US practice. Upon completion of this activity, participants should be better able to: Describe current evidence from pivotal clinical trials, head-to-head comparisons, and practice guidelines on BTK inhibitor efficacy, safety, and mechanistic/selectivity differences, including as single-agent approaches or as part of novel combinations; Select personalized BTK inhibitor therapy for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Recommend sequential BTK inhibitor options for the management of patients with relapsed/refractory CLL or for individuals who develop therapeutic intolerance; and Develop a management plan for adverse events associated with first- and second-generation BTK inhibitors used to treat CLL.
Did you know that the thoracic multidisciplinary team (MDT) has an increasing role in early-stage lung cancer? Join for a discussion on MDT roles. Credit available for this activity expires: 7/20/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/977172?src=mkm_podcast_addon_977172
Social Anxiety Solutions - your journey to social confidence!
Is EFT Tapping scientifically proven to be effective❓ Does tapping for Social Anxiety can bring relief too❓
Go online to PeerView.com/MZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent advances in multiple myeloma (MM) management present a rare opportunity for clinicians, who now have a variety of options to choose from when optimizing patient care. From this starting point, hematology-oncology professionals (including those practicing in community settings) and oncology nurses can leverage the potency of novel therapeutics, including platforms based on CD38 antibodies and novel BCMA-directed therapies, across the spectrum of disease. In this unique program, an interprofessional panel, featuring an academic and community hematologist-oncologist and a nurse professional, will use a series of case-based conversations to demonstrate exactly how to support the MM patient's therapeutic odyssey with innovative therapeutics—and deliver high-quality, collaborative patient care. Upon completion of this activity, participants should be better able to: Apply current evidence and guidelines for the personalized selection of upfront therapy with novel triplets, quadruplets, and maintenance options for patients with newly diagnosed multiple myeloma (MM), including those with transplant-eligible or -ineligible disease, Plan for appropriate sequential treatment options in patients with MM relapsing after 1-3 prior lines of therapy or for those with more heavily pretreated disease, Provide team-based counseling for patients with MM about relevant prognostic factors, high-risk features, sequential management plans, treatment administration and delivery, and drug safety considerations, Develop team-based management strategies for adverse events associated with the use of modern MM treatment regimens, including those containing novel antibody, proteasome inhibitor, and targeted components.
Go online to PeerView.com/MZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent advances in multiple myeloma (MM) management present a rare opportunity for clinicians, who now have a variety of options to choose from when optimizing patient care. From this starting point, hematology-oncology professionals (including those practicing in community settings) and oncology nurses can leverage the potency of novel therapeutics, including platforms based on CD38 antibodies and novel BCMA-directed therapies, across the spectrum of disease. In this unique program, an interprofessional panel, featuring an academic and community hematologist-oncologist and a nurse professional, will use a series of case-based conversations to demonstrate exactly how to support the MM patient's therapeutic odyssey with innovative therapeutics—and deliver high-quality, collaborative patient care. Upon completion of this activity, participants should be better able to: Apply current evidence and guidelines for the personalized selection of upfront therapy with novel triplets, quadruplets, and maintenance options for patients with newly diagnosed multiple myeloma (MM), including those with transplant-eligible or -ineligible disease, Plan for appropriate sequential treatment options in patients with MM relapsing after 1-3 prior lines of therapy or for those with more heavily pretreated disease, Provide team-based counseling for patients with MM about relevant prognostic factors, high-risk features, sequential management plans, treatment administration and delivery, and drug safety considerations, Develop team-based management strategies for adverse events associated with the use of modern MM treatment regimens, including those containing novel antibody, proteasome inhibitor, and targeted components.
Go online to PeerView.com/MZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent advances in multiple myeloma (MM) management present a rare opportunity for clinicians, who now have a variety of options to choose from when optimizing patient care. From this starting point, hematology-oncology professionals (including those practicing in community settings) and oncology nurses can leverage the potency of novel therapeutics, including platforms based on CD38 antibodies and novel BCMA-directed therapies, across the spectrum of disease. In this unique program, an interprofessional panel, featuring an academic and community hematologist-oncologist and a nurse professional, will use a series of case-based conversations to demonstrate exactly how to support the MM patient's therapeutic odyssey with innovative therapeutics—and deliver high-quality, collaborative patient care. Upon completion of this activity, participants should be better able to: Apply current evidence and guidelines for the personalized selection of upfront therapy with novel triplets, quadruplets, and maintenance options for patients with newly diagnosed multiple myeloma (MM), including those with transplant-eligible or -ineligible disease, Plan for appropriate sequential treatment options in patients with MM relapsing after 1-3 prior lines of therapy or for those with more heavily pretreated disease, Provide team-based counseling for patients with MM about relevant prognostic factors, high-risk features, sequential management plans, treatment administration and delivery, and drug safety considerations, Develop team-based management strategies for adverse events associated with the use of modern MM treatment regimens, including those containing novel antibody, proteasome inhibitor, and targeted components.
Go online to PeerView.com/MZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent advances in multiple myeloma (MM) management present a rare opportunity for clinicians, who now have a variety of options to choose from when optimizing patient care. From this starting point, hematology-oncology professionals (including those practicing in community settings) and oncology nurses can leverage the potency of novel therapeutics, including platforms based on CD38 antibodies and novel BCMA-directed therapies, across the spectrum of disease. In this unique program, an interprofessional panel, featuring an academic and community hematologist-oncologist and a nurse professional, will use a series of case-based conversations to demonstrate exactly how to support the MM patient's therapeutic odyssey with innovative therapeutics—and deliver high-quality, collaborative patient care. Upon completion of this activity, participants should be better able to: Apply current evidence and guidelines for the personalized selection of upfront therapy with novel triplets, quadruplets, and maintenance options for patients with newly diagnosed multiple myeloma (MM), including those with transplant-eligible or -ineligible disease, Plan for appropriate sequential treatment options in patients with MM relapsing after 1-3 prior lines of therapy or for those with more heavily pretreated disease, Provide team-based counseling for patients with MM about relevant prognostic factors, high-risk features, sequential management plans, treatment administration and delivery, and drug safety considerations, Develop team-based management strategies for adverse events associated with the use of modern MM treatment regimens, including those containing novel antibody, proteasome inhibitor, and targeted components.
Go online to PeerView.com/MZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent advances in multiple myeloma (MM) management present a rare opportunity for clinicians, who now have a variety of options to choose from when optimizing patient care. From this starting point, hematology-oncology professionals (including those practicing in community settings) and oncology nurses can leverage the potency of novel therapeutics, including platforms based on CD38 antibodies and novel BCMA-directed therapies, across the spectrum of disease. In this unique program, an interprofessional panel, featuring an academic and community hematologist-oncologist and a nurse professional, will use a series of case-based conversations to demonstrate exactly how to support the MM patient's therapeutic odyssey with innovative therapeutics—and deliver high-quality, collaborative patient care. Upon completion of this activity, participants should be better able to: Apply current evidence and guidelines for the personalized selection of upfront therapy with novel triplets, quadruplets, and maintenance options for patients with newly diagnosed multiple myeloma (MM), including those with transplant-eligible or -ineligible disease, Plan for appropriate sequential treatment options in patients with MM relapsing after 1-3 prior lines of therapy or for those with more heavily pretreated disease, Provide team-based counseling for patients with MM about relevant prognostic factors, high-risk features, sequential management plans, treatment administration and delivery, and drug safety considerations, Develop team-based management strategies for adverse events associated with the use of modern MM treatment regimens, including those containing novel antibody, proteasome inhibitor, and targeted components.
Go online to PeerView.com/MZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent advances in multiple myeloma (MM) management present a rare opportunity for clinicians, who now have a variety of options to choose from when optimizing patient care. From this starting point, hematology-oncology professionals (including those practicing in community settings) and oncology nurses can leverage the potency of novel therapeutics, including platforms based on CD38 antibodies and novel BCMA-directed therapies, across the spectrum of disease. In this unique program, an interprofessional panel, featuring an academic and community hematologist-oncologist and a nurse professional, will use a series of case-based conversations to demonstrate exactly how to support the MM patient's therapeutic odyssey with innovative therapeutics—and deliver high-quality, collaborative patient care. Upon completion of this activity, participants should be better able to: Apply current evidence and guidelines for the personalized selection of upfront therapy with novel triplets, quadruplets, and maintenance options for patients with newly diagnosed multiple myeloma (MM), including those with transplant-eligible or -ineligible disease, Plan for appropriate sequential treatment options in patients with MM relapsing after 1-3 prior lines of therapy or for those with more heavily pretreated disease, Provide team-based counseling for patients with MM about relevant prognostic factors, high-risk features, sequential management plans, treatment administration and delivery, and drug safety considerations, Develop team-based management strategies for adverse events associated with the use of modern MM treatment regimens, including those containing novel antibody, proteasome inhibitor, and targeted components.
Go online to PeerView.com/MZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent advances in multiple myeloma (MM) management present a rare opportunity for clinicians, who now have a variety of options to choose from when optimizing patient care. From this starting point, hematology-oncology professionals (including those practicing in community settings) and oncology nurses can leverage the potency of novel therapeutics, including platforms based on CD38 antibodies and novel BCMA-directed therapies, across the spectrum of disease. In this unique program, an interprofessional panel, featuring an academic and community hematologist-oncologist and a nurse professional, will use a series of case-based conversations to demonstrate exactly how to support the MM patient's therapeutic odyssey with innovative therapeutics—and deliver high-quality, collaborative patient care. Upon completion of this activity, participants should be better able to: Apply current evidence and guidelines for the personalized selection of upfront therapy with novel triplets, quadruplets, and maintenance options for patients with newly diagnosed multiple myeloma (MM), including those with transplant-eligible or -ineligible disease, Plan for appropriate sequential treatment options in patients with MM relapsing after 1-3 prior lines of therapy or for those with more heavily pretreated disease, Provide team-based counseling for patients with MM about relevant prognostic factors, high-risk features, sequential management plans, treatment administration and delivery, and drug safety considerations, Develop team-based management strategies for adverse events associated with the use of modern MM treatment regimens, including those containing novel antibody, proteasome inhibitor, and targeted components.
Go online to PeerView.com/MZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent advances in multiple myeloma (MM) management present a rare opportunity for clinicians, who now have a variety of options to choose from when optimizing patient care. From this starting point, hematology-oncology professionals (including those practicing in community settings) and oncology nurses can leverage the potency of novel therapeutics, including platforms based on CD38 antibodies and novel BCMA-directed therapies, across the spectrum of disease. In this unique program, an interprofessional panel, featuring an academic and community hematologist-oncologist and a nurse professional, will use a series of case-based conversations to demonstrate exactly how to support the MM patient's therapeutic odyssey with innovative therapeutics—and deliver high-quality, collaborative patient care. Upon completion of this activity, participants should be better able to: Apply current evidence and guidelines for the personalized selection of upfront therapy with novel triplets, quadruplets, and maintenance options for patients with newly diagnosed multiple myeloma (MM), including those with transplant-eligible or -ineligible disease, Plan for appropriate sequential treatment options in patients with MM relapsing after 1-3 prior lines of therapy or for those with more heavily pretreated disease, Provide team-based counseling for patients with MM about relevant prognostic factors, high-risk features, sequential management plans, treatment administration and delivery, and drug safety considerations, Develop team-based management strategies for adverse events associated with the use of modern MM treatment regimens, including those containing novel antibody, proteasome inhibitor, and targeted components.
Dr. Thomas Sharon, a Nevada nurse practitioner, is ready to provide you with evidence-base relief of the symptoms of Post Covid Syndrome and prevent complications.
Each day, more than 130 people die from opioid overdoses. Opioids are a class of drugs that include prescription pain relievers like oxycodone. They also include illegal drugs like heroin. In 2019, 1.6 million Americans had an opioid addiction. This is also known as opioid use disorder. Yet effective medications—like buprenorphine, methadone, and naltrexone—are prescribed to only a fraction of people with opioid use disorder. Patients often receive such medications in an opioid treatment program. Methadone, for example, can only be given in a certified treatment program. Primary care physicians can apply for a waiver to prescribe buprenorphine. However, less than 10% of U.S. primary care providers have a buprenorphine waiver. Given the limited number of patients that each physician can treat, involving pharmacists in opioid treatment may improve access. The Doctor Patient Forum's Mission Statement is to advocate, educate, and defend the rights of patients, to protect all providers (including prescribers and pharmacists) who tirelessly work to treat their patients, and to bring awareness to the general public regarding restrictions upon medical providers. We are fighting for a return to individualized patient care instead of using guidelines and laws based on little evidence using arbitrary thresholds. Contrary to what has been said, we are not “industry funded.” We haven't taken any money from pharma. We are not being paid to promote opioids. We are simply chronic pain and illness patients who are fighting as hard as we can to effect change in this broken system where the patient's voice is non-existent. For part 4 of the series, we're honored to have Ms. Bev Schechtman. Ms. Schectman is one of the founding members of Don't Punish Pain Rally and is the VP of The Doctor Patient Forum. She grew up in northern New Jersey, and has lived in the Raleigh area in North Carolina since 2009. Bev has been married to Randy for 18 years, and has two teenage daughters, Emma, 17, and Livvy,13. She also has a 3-year-old Aussidoodle, Griffin. Bev has been living with Crohn's Disease and Psoriatic Arthritis for over two decades. She first contacted Claudia Merandi after being denied opioid medication while hospitalized for kidney stones in 2017.She was denied due to being a survivor of childhood sexual abuse. Bev is a passionate advocate for people with chronic pain and illness as well as those who have PTSD/ survived sexual assault/abuse. Bev has her B.A. in Psychology and hopes to get her M.S.W. in the near future. Bev is a voracious reader and researcher. She is passionate about understanding why pain patients are being mistreated so she can educate other patients and empower them to fight back. Bev hopes her advocacy work brings awareness to the anti-opioid zealots who are profiting off of punishing pain patients while pretending to care about those with addiction. She also believes strongly in Harm Reduction efforts. Learn more about your ad choices. Visit megaphone.fm/adchoices
Each day, more than 130 people die from opioid overdoses. Opioids are a class of drugs that include prescription pain relievers like oxycodone. They also include illegal drugs like heroin. In 2019, 1.6 million Americans had an opioid addiction. This is also known as opioid use disorder. Yet effective medications—like buprenorphine, methadone, and naltrexone—are prescribed to only a fraction of people with opioid use disorder. Patients often receive such medications in an opioid treatment program. Methadone, for example, can only be given in a certified treatment program. Primary care physicians can apply for a waiver to prescribe buprenorphine. However, less than 10% of U.S. primary care providers have a buprenorphine waiver. Given the limited number of patients that each physician can treat, involving pharmacists in opioid treatment may improve access. The Doctor Patient Forum's Mission Statement is to advocate, educate, and defend the rights of patients, to protect all providers (including prescribers and pharmacists) who tirelessly work to treat their patients, and to bring awareness to the general public regarding restrictions upon medical providers. We are fighting for a return to individualized patient care instead of using guidelines and laws based on little evidence using arbitrary thresholds. Contrary to what has been said, we are not “industry funded.” We haven't taken any money from pharma. We are not being paid to promote opioids. We are simply chronic pain and illness patients who are fighting as hard as we can to effect change in this broken system where the patient's voice is non-existent. For part 4 of the series, we're honored to have Ms. Bev Schechtman. Ms. Schectman is one of the founding members of Don't Punish Pain Rally and is the VP of The Doctor Patient Forum. She grew up in northern New Jersey, and has lived in the Raleigh area in North Carolina since 2009. Bev has been married to Randy for 18 years, and has two teenage daughters, Emma, 17, and Livvy,13. She also has a 3-year-old Aussidoodle, Griffin. Bev has been living with Crohn's Disease and Psoriatic Arthritis for over two decades. She first contacted Claudia Merandi after being denied opioid medication while hospitalized for kidney stones in 2017.She was denied due to being a survivor of childhood sexual abuse. Bev is a passionate advocate for people with chronic pain and illness as well as those who have PTSD/ survived sexual assault/abuse. Bev has her B.A. in Psychology and hopes to get her M.S.W. in the near future. Bev is a voracious reader and researcher. She is passionate about understanding why pain patients are being mistreated so she can educate other patients and empower them to fight back. Bev hopes her advocacy work brings awareness to the anti-opioid zealots who are profiting off of punishing pain patients while pretending to care about those with addiction. She also believes strongly in Harm Reduction efforts. Learn more about your ad choices. Visit megaphone.fm/adchoices
To obtain credit – Click Here For more information – Click Here
This week on the podcast, I welcome Dr James Greenblatt. Dr Greenblatt is a pioneer in the field of integrative medicine and has treated patients since 1988. He is dedicated to the Personalized, Evidence-Based Treatment of Mental Illness. After receiving his medical degree and completing his psychiatry residency at George Washington University, Dr. Greenblatt completed a fellowship in child and adolescent psychiatry at Johns Hopkins Medical School. He currently serves as the Chief Medical Officer at Walden Behavioral Care in Waltham, MA and serves as an Assistant Clinical Professor of Psychiatry at Tufts University School of Medicine and Dartmouth College Geisel School of Medicine. Dr. Greenblatt has lectured internationally on the scientific evidence for nutritional interventions in psychiatry and mental illness. He is the author of seven books, including Finally Focused: The Breakthrough Natural Treatment Plan for ADHD. He is the founder of Psychiatry Redefined, an educational platform dedicated to the transformation of psychiatry, which offers online CME-approved courses, webinars, and fellowships for professionals about functional and integrative medicine for mental illness Need help with improving your child's health using integrative approaches?Check out my Instagram page -full of information, latest research, tips and tools for parents who want to be more effective with improving their children's health and behavior.Want to work with me? Contact us here.Episode HighlightsThe nutritional approaches to psychiatric conditions in childrenMedications for children with ADHDNutritional deficiencies in children with ADHDUnderlying root causes for ADHDOPCs and Omega 3sShow Noteshttps://www.psychiatryredefined.org/finally-focused-book/Music CreditFirst Light - Atch https://soundcloud.com/atch-musicCreative Commons — Attribution 3.0 Unported — CC BY 3.0
This show is hosted by Advanced Therapeutic Solutions for Anxiety's summer intern Iris Li (she/her), a senior from Wellesley College majoring in psychology and chemistry. Our special guest, Mark Reinecke, Ph.D., ABPP, ACT joins the show to talk about his experiences in the field of clinical psychology and tells fascinating stories about his journey, research, and clinical work. Read more about Dr. Reinecke here: https://markreinecke.com/about/ Educational Journey (00:57) Q1: Could you please tell us about your educational background and how you made the decision to do psychiatry/clinical psychology? John Flavell: http://psychology.iresearchnet.com/developmental-psychology/history-of-developmental-psychology/john-flavell/ Walter Michael: https://www.psychologicalscience.org/observer/remembering-walter-mischel Alan Fogel: https://prabook.com/web/alan_dale.fogel/3612395 Jerry Gruen: https://www.linkedin.com/in/jerry-gruen-19a801122 Aaron Beck: https://beckinstitute.org/team/dr-aaron-t-beck/ Cognitive Behavioral Therapy (CBT) and Dialectical Behavioral Therapy (DBT): https://www.cbc-psychology.com/treatment-wellness Working in the Clinical Field (12:35) Q2: How much do you emphasize the Attachment Theory in your practice of Cognitive Behavioral Therapy (CBT)? Q3: Is there a way to form secure attachment during adolescence or young adulthood if they missed the chance during childhood? Attachment Theory, John Bolwby, and Mary Ainsworth: https://www.verywellmind.com/what-is-attachment-theory-2795337 Q4: What is the most different thing between working with children, adolescents, and adults with mental health problems? Parent-Child Interaction Therapy (PCIT): https://www.advancedtherapeuticsolutions.org/about/anxiety-specialists-in-oak-brook/evidence-based-treatments-for-anxiety-depression-and-behavior-conduct-problems/ Q5: What are some mental health disorders that are so difficult to treat that we can regard them as the “cancer” in the mental health field? David Clark and panic disorder: https://www.psychologytools.com/self-help/panic-attacks-and-panic-disorder/ National Suicide Prevention Lifeline: https://suicidepreventionlifeline.org/ Q6: Could you tell us about the personality disorders in children and adolescents? Personality Disorders in Childhood and Adolescence: https://www.amazon.com/Personality-Disorders-Childhood-Adolescence-Freeman/dp/0471683043/ref=sr_1_3?dchild=1&keywords=reinecke+personality+disorders&qid=1602705931&s=books&sr=1-3 Q7: Why is Cognitive Behavioral Therapy (CBT) so prominent in all kinds of psychotherapy? Evidence-Based Treatment: https://www.advancedtherapeuticsolutions.org/about/anxiety-specialists-in-oak-brook/evidence-based-treatments-for-anxiety-depression-and-behavior-conduct-problems/ Q8: What is the best part of your clinical experience? Q9: As you work with patients, how are you taking care of your own mental health? Evenly hovering: https://www.encyclopedia.com/psychology/dictionaries-thesauruses-pictures-and-press-releases/evenly-suspended-attention Professional Development for Students (32:50) Q10: How do you think students should prepare themselves before entering grad school? Q11: How important is it for students to get publications before applying to grad school? Future of Mental Health (37:36) Q12: How can mental health improve in the Asian community? Q13: Where is the future of the mental health field? The Internship Crisis: https://www.advancedtherapeuticsolutions.org/about/professional-development/undergraduate/psychology-internship-for-college-students/
The Psychology of Self-Injury: Exploring Self-Harm & Mental Health
A lot of therapies address the context in which nonsuicidal self-injury (NSSI) and self-harm may occur, but only a few treatments have been designed to address NSSI specifically. In this episode, we dive into one of these treatments: Treatment for Self-Injurious Behaviors (T-SIB). Dr. Peggy Andover, its lead developer, walks us through the 9 sessions of T-SIB, including the personalized modules of sessions 7 & 8.Learn more about Dr. Andover and her work in the Mood and Behaviors Lab at https://www.fordham.edu/info/23638/mood_and_behaviors_lab and reach her at andover@fordham.edu. Follow her on Twitter @DrPeggyAndover. Below are links to some of her research and the resources referenced in this episode:Moderators of treatment response to an intervention for nonsuicidal self-injury in young adults (2020)An intervention for nonsuicidal self-injury in young adults: A pilot randomized controlled trial (2017)Development of an intervention for nonsuicidal self-injury in young adults: An open pilot trial (2015)Follow Dr. Westers on Instagram and Twitter (@DocWesters). To join ISSS, visit itriples.org and follow ISSS on Facebook and Twitter (@ITripleS).
CME credits: 1.00 Valid until: 25-11-2021 Claim your CME credit at https://reachmd.com/cme/pulmonary-medicine/ssc-ild-importance-early-diagnosis-patient-centered-communication-and-evidence-based-treatment/11946/ The goal of this activity is to improve the awareness, knowledge, and competency of pulmonologists, rheumatologists, radiologists, dermatologists and primary care physicians in the diagnosis, treatment and a multidisciplinary approach to the longitudinal management of Systemic Sclerosis Interstitial Lung Disease (SSc-ILD).
CME credits: 1.00 Valid until: 25-11-2021 Claim your CME credit at https://reachmd.com/cme/pulmonary-medicine/ssc-ild-importance-early-diagnosis-patient-centered-communication-and-evidence-based-treatment/11946/ The goal of this activity is to improve the awareness, knowledge, and competency of pulmonologists, rheumatologists, radiologists, dermatologists and primary care physicians in the diagnosis, treatment and a multidisciplinary approach to the longitudinal management of Systemic Sclerosis Interstitial Lung Disease (SSc-ILD).
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.11.15.383448v1?rss=1 Authors: Lin, F. P. Abstract: BACKGROUND: The advances in genome sequencing technologies have provided new opportunities for delivering targeted therapy to patients with advanced cancer. However, these high-throughput assays have also created a multitude of challenges for oncologists in treatment selection, demanding a new approach to support decision-making in clinics. METHODS: To address this unmet need, this paper describes the design of a symbolic reasoning framework using the method of hierarchical task analysis. Based on this framework, an evidence-based treatment recommendation system was implemented for supporting decision-making based on a patient's clinicopathologic and biomarker profiles. RESULTS: This intelligent framework captures a six-step sequential decision process: (1) concept expansion by ontology matching, (2) evidence matching, (3) evidence grading and value-based prioritisation, (4) clinical hypothesis generation, (5) recommendation ranking, and (6) recommendation filtering. The importance of balancing evidence-based and hypothesis-driven treatment recommendations is also highlighted. Of note, tracking history of inference has emerged to be a critical step to allow rational prioritisation of recommendations. The concept of inference tracking also enables the derivation of a novel measure -- level of matching -- that helps to convey whether a treatment recommendation is drawn from incomplete knowledge during the reasoning process. CONCLUSIONS: This framework systematically encapsulates oncologist's treatment decision-making process. Further evaluations in prospective clinical studies are warranted to demonstrate how this computational pipeline can be integrated into oncology practice to improve outcomes. Copy rights belong to original authors. Visit the link for more info
As with ever developing science we come across lots of treatments and therapies which is both beneficial but also adds to dilemma as which one to follow especially those treatments which still in research or not got a patent. Here is the guide for the same --- Send in a voice message: https://anchor.fm/dr-richa-sharma/message
In today’s episode of Sundays With Stories, Stanton and Zach discuss current events. This week a New York Times article bemoaned the failure of addiction specialists to adopt a proven tool for treating drug addiction, “contingency management.” That is, paying meth, cocaine et al. users for abstinence. That’s right: experienced, one might say addicted, “speed” (“crank”) users will desist drug use if you give them money — and not colossal sums at that. This has been Carl Hart’s research with meth, and the University of Vermont group’s under Warren Bickle with cocaine. The same benefits of providing alternative rewards have been shown in Bruce Alexander’s Rat Park and the Baltimore City Hospital group’s research with street drinkers. What does this tell us? That drug and alcohol addiction is not a runaway train resistant to environmental factors and rewards. Which is useful to know. However, Zach and Stanton question who is creating these rewards. There is a bit of science-gone-amok to the image of men in white coats divvying out money for drug and alcohol users, even those with the worst usage patterns, to be “good.” And what happens when the rewards, the gravy train, stops? You tell us. But Harvard’s Global Anti-Tobacco Program offered a hint. While investigating the effectiveness of nicotine replacement therapy (NRT) for those who quit smoking, the program’s chief investigators found that, in the long run, those who quit on their own did as well as, or better than, those who rely on NRT. In fact, the most addicted smokers were the worst at keeping off the drug using NRT. This finding held true even though NRT was “proven effective in the laboratory.” Zach and Stanton then speak of people managing their own contingencies. That is, their finding real-world reasons to quit or cut back their addictions. Most important of all (with a nod to Steve Slate et al.’s Freedom Model”) is people’s belief that they can control their own drug use and lives. This thinking belies NIDA Director Nora Volkow’s 2007 unwise piece “Addiction Is a Disease of Free Will” — which, per Stanton’s urging, Volkow seems to be abandoning. What is she replacing this ill-conceived notion with? What Stanton and Zach practice in their Life Process Program: creating lives worth living and worlds people want to occupy. This is a tough task. But, once again, including a review of America’s ill-fated (drug deaths are ramping out of control) enthusiasm for medicine-assisted treatment for opioid addiction, there is no long-term alternative. Finally, Zach reviews SMART Recovery’s belated shift to “abstinence from addiction” in place of its former “desist all use” basis — as the user chooses. They agree in their admiration for Tom Horvath/SMART Recovery’s remarkable success at creating an alternative to AA. At the same time, they embrace SMART’s long-awaited and necessary shift to Harm Reduction. Stanton and Zach end their podcast by wondering how decades of addiction research and both positive and negative experiences with drugs have left even our “advanced guard” (i.e., policy reformists like the Ethan Nadelmann-founded DPA) so shorn of an appreciation for the interchange between people’s lived experience (their actual lives) and addiction. Come join Stanton and Zach as they reveal a little secret. That is, the best science, policy, and treatment involve common sense. At the same time, they say, free yourself from decades-old failed thinking. - - - - - - - - - - LPP MAIN WEB SITE http://LifeProcessProgram.com --- Send in a voice message: https://anchor.fm/lifeprocessprogram/message
In this episode, we speak with two amazing guests, Kimberly and Matt Teitter. Matt and Kimberly have been married for ten years. Kimberly is a clinical psychologist at the Utah Center for Evidence Based Treatment, and Matt is an assistant principal, and Bishop of their ward in Salt Lake City.In this episode, they discuss their experience as an interracial couple in the Church, their experience of privilege in the different roles they have, what it’s been like navigating local leadership right now, and how we can make our spaces safer for minorities of any kindEven with their extremely busy schedule, Kimberly and Matt were kind enough to join us for a late night conversation. We just wanted to preface that they have two adorable kids, and in the podcast, you’ll hear some family sounds in the background as we talk. If you’d like to read a transcript of the conversation, head to the website at faithmatters.org and click on the post with this conversation.We’re so grateful that Matt and Kimberly came on the podcast, and hope you enjoy the conversation.
A young male patient woke with an acute onset of constant, shooting shoulder pain, is painful into abduction, reluctant to lift his arm, and feels like he's losing shoulder strength. He has no recent history of injury. Can you diagnose this unusual cause of shoulder pain, based on this patient's symptoms and physical tests? What are your differential diagnoses and red flags to keep in mind with this patient? In this podcast, Jo Gibson puts your knowledge of shoulder pain and diagnostic skills to the test, and explores how you can treat patients with this diagnosis. Links associated with this episode: Download and subscribe to the podcast on iTunes Download the podcast now using the best podcast app currently in existence - Overcast Listen to the podcast on Spotify Improve your diagnosis of acute shoulder pain with 3 free videos with Jo Gibson Improve your confidence and clinical reasoning with a free trial Clinical Edge membership Let David know what you liked about this podcast on Twitter Review the podcast on iTunes Like the podcast on Facebook Infographics by Clinical Edge Jo Gibson on Twitter Articles associated with this episode: CLICK HERE to download the articles associated with this podcast Clarke CJ, Torrance E, McIntosh J, Funk L. Neuralgic amyotrophy is not the most common neurologic disorder of the shoulder: a 78-month prospective study of 60 neurologic shoulder patients in a specialist shoulder clinic. Journal of shoulder and elbow surgery. 2016 Dec 1;25(12):1997-2004. Cup EH, Ijspeert J, Janssen RJ, Bussemaker-Beumer C, Jacobs J, Pieterse AJ, van der Linde H, van Alfen N. Residual complaints after neuralgic amyotrophy. Archives of physical medicine and rehabilitation. 2013 Jan 1;94(1):67-73. DO MAGDALIA PB. Neuralgic Amyotrophy. Challenging Neuropathic Pain Syndromes: Evaluation and Evidence-Based Treatment. 2017 Nov 12:197. Feinberg JH, Nguyen ET, Boachie‐Adjei K, Gribbin C, Lee SK, Daluiski A, Wolfe SW. The electrodiagnostic natural history of parsonage–turner syndrome. Muscle & nerve. 2017 Oct;56(4):737-43. Lustenhouwer R, Cameron IG, van Alfen N, Oorsprong TD, Toni I, van Engelen BG, Groothuis JT, Helmich RC. Altered sensorimotor representations after recovery from peripheral nerve damage in neuralgic amyotrophy. Cortex. 2020 Feb 28. Seror P. Neuralgic amyotrophy. An update. Joint Bone Spine. 2017 Mar 1;84(2):153-8. Get access to free videos with Jo Gibson on diagnosis of shoulder pain at clinicaledge.co/shoulder
George Floyd’s death — as just the latest example of a black person dying at the hands of law enforcement — has shaken, angered, agitated and, some say, awakened the nation, setting off waves of sometimes-violent protests against racism and police brutality. Days later, Russell M. Nelson, president of The Church of Jesus Christ of Latter-day Saints, a faith with its own racist history, took to social media, condemning prejudice, calling racists to repentance and decrying the lawlessness that has erupted. Two African American Latter-day Saints join this week’s “Mormon Land” podcast to discuss systemic racism, protests and the church’s delayed response. Both LaShawn Williams, an assistant professor of social work at Utah Valley University, and Kimberly Applewhite, a psychologist with the Utah Center for Evidence Based Treatment, say society, the nation, their church and individuals can and must do more to wipe out the sin of racism.
Megan Sutton joins us for an in depth look at a few of her Tactus Therapy apps. Megan is passionate about connecting clinicians with evidence-based tools to treat aphasia. Over the past 9 years, Megan has built and refined some of the best tools on the digital market to address expressive and receptive language needs. In today's talk, Megan highlights the specific evidence-based techniques that support each app. For example, in the Naming Therapy app, Megan consulted the literature regarding PCA (Phonological components analysis), SFA (Semantic Feature Analysis), and RET (Response Elaboration Training). Join us as Megan reveals that including evidence-based treatment and patient-centered care are achievable in everyday practice. Visit the show notes for more useful information at speechuncensored.com/podcastepisodes/s2e7-delivering-evidence-based-treatment-using-tactus-therapy-apps-with-megan-sutton-ms-ccc-slp-c Send in a voice message: https://anchor.fm/speech-uncensored/message
Megan Sutton joins us for an in depth look at a few of her Tactus Therapy apps. Megan is passionate about connecting clinicians with evidence-based tools to treat aphasia. Over the past 9 years, Megan has built and refined some of the best tools on the digital market to address expressive and receptive language needs. In today’s talk, Megan highlights the specific evidence-based techniques that support each app. For example, in the Naming Therapy app, Megan consulted the literature regarding PCA (Phonological components analysis), SFA (Semantic Feature Analysis), and RET (Response Elaboration Training). Join us as Megan reveals that including evidence-based treatment and patient-centered care are achievable in everyday practice. --- Send in a voice message: https://anchor.fm/speech-uncensored/message
Session ‘Evidence Based Treatment of Sepsis II’ from the 2nd World Sepsis Congress. Featuring Peter Hjortrup, Naomi Hammond, Yasser Sakr, John Myburgh, Anders Perner, Didier Payen, and Markus Weigand as chair. More info: www.worldsepsiscongress.org
Session ‘Evidence Based Treatment of Sepsis I’ from the 2nd World Sepsis Congress. Featuring Daniel de Backer, Massimo Antonelli, Marlies Ostermann, Kathy Rowan, Jean-Louis Teboul, Madiha Hashmi, and Marc Ziegenfuss as chair. More info: www.worldsepsiscongress.org
In the field of Couples Therapy there has been very little research on gay couples. Fortunately, more and more is being done all of the time. It is important for Couples Therapists to be educated on this research and also understand how they can communicate in a way that is inclusive. This episode was with Alapaki Yee and Salvatore Garanzini, the founders of the Gay Couples Institute with locations in San Francisco, San Diego, and New York. They created the institute because they disagreed with many of the things their gay and lesbian friends were being told in their own relationship therapy that were not based on any research. They both have advanced training in the Gottman method and Salvatore is a Certified Gottman Therapist. They continue to do research and are at the forefront of what is working in couples therapy. Please, please, please read the article below about their work!!! The Couples Therapist Couch is the podcast for Couples Therapists about the practice of couples therapy. The host, Shane Birkel, interviews an expert in the field of couples therapy each week. There is an episode released every Tuesday. Please rate and subscribe to the podcast for more great episodes! Click here to join the Couples Therapist Couch Facebook Group. Resources Visit The Gay Couples Institute website at gaycouplesinstitute.org Article: Gottman Method Couples Therapy Established as Evidence-Based Treatment for Same-Sex Couples
On episode 013 of the Swallow Your Pride Podcast we have Rebecca Levy. Rebecca is an SLP currently in the role of Clinical Program Consultant for ACP’s Synchrony dysphagia program. Rebecca has worked in healthcare for over 11 years. Although she spent the first 2 years of her career in special education, she quickly realized that she had a passion for the geriatric setting and specifically working with patients with dysphagia. She spent about 8 years in a SNF setting and 5 of those years she was a Director of Rehabilitation for her therapy program but never stepped away from treating. She also spent some time doing private home health and worked on a mobile van completing videofluoroscopy. Rebecca’s current role of clinical consultant is probably her most fulfilling, helping to educate other SLPs and helping them to get superior outcomes with their patients!In this episode, we discuss ALL things exercise! Exercises, exercises, and more exercises! Rebecca goes through all 17 components of the MBSimp and provides evidence-based exercises for each swallowing impairment. The show notes for this episode can be found at www.swallowyourpridepodcast.com and there is a cheat sheet chart of all of the impairments, muscles and cranial nerves involved, as well as exercises for each component!To learn more about the Medical SLP Collective, an exclusive community for Medical SLPs with new peer-reviewed resources, handouts, and videos distributed weekly, monthly ASHA CEU webinars, and a private forum on Facebook, or on the website to get answers to all of your burning clinical questions, check out MedSLPCollective.com Download Ep. 013 Show Notes Download Ep. 013 Transcript This Month’s Featured Affiliates: If you like our work, support us on Patreon for as little as a dollar a month! Previous Next Previous Next
When I was married to a good man suffering from this disease, I went to the bookstore on a regular basis looking for books about how to help my husband get sober. What I found was tons of stories and memoirs about brave men and women who have struggled with addiction and found a way to get sober. But there were no stories about the women who loved them. So late one night when I was in the bookstore, I made a promise to God that if I ever found the answers, I would spend the rest of my life teaching other women. And that’s exactly what I have been doing for over six years. My three online, do-at-your-own-pace programs are designed just for wives, girlfriends, and mothers who love someone who suffers from alcoholism or substance abuse. Today we are going to talk about something a little bit different: rehabilitation. I get asked questions like, "Does rehab really work?" and "What makes a good rehab?" all the time. But before I tell you the top ten things you need to know about rehab, I want to share my experience with getting my ex-husband into a rehabilitation program. I go more into detail about it in the Love Over Mistakes program, but I'll keep this story short. Several years ago, at one of my many trips to the bookstore, I came across a book written by a man who started his own fancy rehab center based on extensive research. His approach was dramatically different than most 12-step rehabs, and there was something very persuasive about his writing. The more I read his book, the more I was convinced that I needed to get my husband to Malibu so he could experience the breakthrough this author was promising. I spent days dreaming of what it would be like to have him sober for good. How he would be the loving, supportive husband I always knew he could be. My children would finally get the engaged dad who was sober and loving all the time. Our vacations and holidays would not be centered around his next drink. But there was an issue: this rehab cost $60,000. We were in our twenties at the time and coming up with that kind of money seemed impossible because we lived paycheck to paycheck. I called our health insurance agency, and they told me they would pay for some of it. Then I called our family and my father kindly offered to take out a second mortgage on his apartment. I drained our bank account, plus his family agreed to pay a portion as well. After a month of planning, the money was there. Now it was time to fill him in. I planned on hosting an intervention, but (since God had a better idea) the night before our intervention was going to take place, he overdosed on drugs. I’m not sure what kind of drugs he took, but he came into my bedroom and was talking really fast and acting crazy. I’ve never seen anything like it. He had always done his drugs away from the house. It scared me to the core. I was watching a stranger in my bedroom who had absolutely no resemblance to the man I married. I prayed that the kids would stay asleep so they would not witness his paranoid behavior and hours later he settled down. I told him that we had planned for him to leave, take a month off of work, and attend a rehab. That everything had been taken care of for him. I didn’t know how he would react and I was prepared for the worst. But then he looked at me and said he was tired of living like this. He agreed to go just four hours before his scheduled flight to the rehab center. Like I said, I go more into what happened in the next month in the Love Over Mistakes program. But for now, I want to share with you the top ten tips that you will find helpful when considering rehabs. I wish I had these tips all those years ago. He will NOT lose his job if he goes to rehab. The Americans with Disabilities Act and the Family Medical Leave Act guarantee that addicts and alcoholics who wish to undergo treatment for substance abuse will be given the time they need to do so by their employers and that their jobs will be saved for them while they are away. These laws do not guarantee a paycheck while they are gone. Some employers will pay a certain percentage of their paycheck, some will not. Rehab success rates can be misleading. According to the National Center on Addiction and Substance Abuse, the rehab community claims a 30% success rate, but they only count people who complete the programs. 70-80% have dropped out within 3-6 months. I am not sharing these numbers to discourage you or put down the rehab industry. But if you're thinking, like I did, that just getting them to rehab will be the solution, you might need to adjust your expectations. 12-step programs are usually part of the aftercare suggestions. Eventually, your partner will be encouraged by the rehab to attend a 12-step aftercare program. If he or she attended rehab and graduated, but doesn’t feel comfortable attending 12-step, higher-power programs on a consistent basis, they don't have a lot of other choices for aftercare treatment other than therapy. Many rehabs don’t follow up with alumni. Once you graduate from the program, you’re pretty much on your own. Of the rehabs that I know of, most do a decent job of trying to suggest ways to manage your aftercare. But when you walk out those doors, it’s up to your loved one to work their own recovery. Look for a rehab that practices EBT. EBT stands for Evidence-Based Treatment. 12-step programs have saved many lives, but studies have shown that we need to also include a medical model for treatment. A medical model includes an assessment from a psychologist or psychiatrist who is trained in addiction medicine, an intervention, therapy, psychopharmacology (a fancy word that means medication), and an inpatient program or outpatient program that offers quality care. You can go to the American Society of Addiction Medicine for a directory. Rehab is expensive. Even non-profit rehabs usually cost over $20,000 for 30 days. Recovery information you read on the internet is often published by a rehab, not a research-based institute. If you’re on a website reading about addiction and they have a 1-800 number or any ads for a rehab, chances are, the website is published by a rehab. I’m not saying there isn’t good information out there on the internet to read about addiction but know the source. Sometimes what looks like well-written articles are just marketing websites. They might tell you relapse is part of his recovery. According to the National Institute on Drug Abuse, a government-funded program, relapse in addiction resembles relapse in other chronic diseases. You may have heard people compare the disease of addiction to diabetes. Well, if you're a type-1 diabetic and you’re getting successful treatment, you have a 30-50% chance of relapse. If you suffer from addiction you have a 40-60% chance of relapse. If you suffer from asthma, your chances of relapse are even greater at 50-70%. Just because they attend rehab, doesn't mean there isn't a good chance they will relapse just like any other chronic disease. When that happens, we don’t need to think of it as a failure. Rather, a treatment needs to be reinstated or readjusted or another treatment needs to be introduced. You need to recover too. You have been hurt, damaged, and lied to by this disease. Getting your loved one help is good. But if he or she refuses or agrees, you need to find support and answers too. If you’re anything like me, when my ex-husband went to rehab, I was left feeling lonely, angry, and worried. I needed to work my own program and get educated on what I needed to do when he came back. If you’re interested and you want to learn about our online, do-at-your-own-pace programs, you can click here. If they don’t want help, you won't be able to change their heart. I know that’s hard to hear, but if you really want them to get sober, they have to want it too. However, you don’t need to wait for them to get sober for you to start to feel better. You can take control of your decisions and reactions and your recovery. I believe in you. You’re not powerless over this disease. You don’t need to wait for them to get sober to start to feel better. We are in this together. P.S. I hope you will join me in one of our programs. You have lifetime access, they are private and confidential, and, remember - you need recovery if he gets sober or not.
Did you know the recommendations for treatment of children and youth with ADHD varies depending on the patient's age? The guidelines for treating young children with ADHD between the ages of 3 and 6 are to provide behavior therapy as the first line of treatment.
Did you know the recommendations for treatment of children and youth with ADHD varies depending on the patient’s age? The guidelines for treating young children with ADHD between the ages of 3 and 6 are to provide behavior therapy as the first line of treatment.
Manik Bhat is the CEO and cofounder of Healthify. After spending time connecting patients to social services in the Baltimore community and dealing with the poor state of affairs in managing a patient's social needs, he decided to start Healthify to improve the status quo. Manik hopes to change the way we coordinate around an individual's social needs and prove that addressing social determinants is not only the morally just thing to do but is also the fiscally responsible thing to do in the era of value. His work has been featured at TEDMED, the Center for Healthcare Strategies, the Robert Wood Johnson Foundation, and in Forbes. Healthify is currently active in over 24 states and growing. Twitter: @HealthifyUS 00:00 What Social Determinants are.03:15 A percentage breakdown of what causes/affects outcomes.03:45 “The reality is that anywhere from 35-60% of our health outcomes are determined by Social Determinants.”05:00 “80% of money is spent on medical services when only 20% of these services determine health outcomes.”05:10 Long-term thinking vs. Short-term thinking in the healthcare industry.07:40 Addressing Social Determinants in a value-based environment vs. a fee-for-service environment.10:00 How Healthify got its start.17:00 Healthcare and social programs in place to combat Social Determinants.19:30 Making Social Determinants evidence-based.20:30 What using Healthify looks like.21:30 The patient-facing and staff-facing ends of Healthify.24:15 How Healthify can facilitate between the patient, community-based organizations, and medical providers.27:15 How Healthify qualifies services and providers.29:00 How Healthify has evolved.32:15 The importance of constant training for community health workers.33:50 Three lessons: benefit-driven messaging to the patient, rigourous training to the staff, and social service engagement.34:30 You can find out more at Manik@healthify.us or https://www.healthify.us/
In this episode of the Integral Health Resources Podcast, I reflect on the notion of “evidenced-based” treatments and practice. Topics include: Evidence-based treatment of mental health problems The process of conducting research (especially in the field of mental health counseling) … Continue reading →
Editor-in-chief Shawn Kennedy and Clinical Editor Betsy Todd present the highlights of the June issue of the American Journal of Nursing. This month's cover shows nurses at the Dana-Farber Cancer Institute practicing mindfulness in a healing garden. Our first CE, “Early Percutaneous Endoscopic Gastrostomy Tube Dislodgment,” presents a real case of PEG tube dislodgement and subsequent sepsis leading to the patient's death. Our second CE, “Epilepsy Update Part 2: Nursing Care and Evidence-Based Treatment,” addresses the most important aspects of assessing and caring for patients with epilepsy. The feature article “Cultivating Quality: Cultivating Mindfulness to Enhance Nursing Practice” describes a multifaceted mindfulness program introduced for members of a nursing team. And our “Culturally Competent Care: Using the ESFT Model in Nursing” article discusses the need for nurses to communicate effectively with diverse populations and how health care disparities can be reduced through culturally competent care. In addition, there's News, Reflections, Drug Watch, Art of Nursing, and more.
Editor-in-chief Shawn Kennedy and Clinical Editor Betsy Todd present the highlights of the June issue of the American Journal of Nursing. This month’s cover shows nurses at the Dana-Farber Cancer Institute practicing mindfulness in a healing garden. Our first CE, “Early Percutaneous Endoscopic Gastrostomy Tube Dislodgment,” presents a real case of PEG tube dislodgement and subsequent sepsis leading to the patient’s death. Our second CE, “Epilepsy Update Part 2: Nursing Care and Evidence-Based Treatment,” addresses the most important aspects of assessing and caring for patients with epilepsy. The feature article “Cultivating Quality: Cultivating Mindfulness to Enhance Nursing Practice” describes a multifaceted mindfulness program introduced for members of a nursing team. And our “Culturally Competent Care: Using the ESFT Model in Nursing” article discusses the need for nurses to communicate effectively with diverse populations and how health care disparities can be reduced through culturally competent care. In addition, there’s News, Reflections, Drug Watch, Art of Nursing, and more.
Our guest this afternoon is David Sheff, author of Clean: Overcoming Addiction and Ending America’s Greatest Tragedy. We will be discussing the addiction treatment industry and what it means to be evidence based.
By Marcus A. Neubauer. Study results suggest that treating non-small-cell lung cancer patients per these guidelines is a cost-effective strategy for delivering care.
© 2020-2025 Ivy Podcast Discovery LLC
